Tower Research Capital (TRC)’s ProShares Ultra CRCL CRCA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-9
Closed -$372 – 5797
2026
Q1
$372 Buy
+9
New +$374 ﹤0.01% 4893

Other funds holding CRCA

Tower Research Capital (TRC)'s CRCA Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of ProShares Ultra CRCL (CRCA) in Q2 2026, closing a stake of 9 shares — an estimated $372 sold.

Tower Research Capital (TRC) first reported a position in CRCA in Q1 2026 and held it in 1 quarter. The position peaked at $372 in Q1 2026. 7 funds tracked by Wall St. Rank hold CRCA as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining ProShares Ultra CRCL position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9 ProShares Ultra CRCL shares in Q2 2026, an estimated $372.
  • Tower Research Capital (TRC) first reported a position in ProShares Ultra CRCL in Q1 2026 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s ProShares Ultra CRCL position peaked at $372 in Q1 2026.
  • 7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.